Targeting the apoptotic pathway in chondrosarcoma using recombinant human Apo2L/TRAIL (dulanermin), a dual proapoptotic receptor (DR4/DR5) agonist

Molecular Cancer Therapeutics

Volumn 11, Issue 11, 2012, Pages 2541-2546

  Subbiah, Vivek ^a   Brown, Robert E ^b   Buryanek, Jamie ^b   Trent, Jonathan ^c   Ashkenazi, Avi ^d   Herbst, Roy ^e   Kurzrock, Razelle ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MIAMI   (United States)

^d GENENTECH INC   (United States)

^e Department of Medical Oncology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DULANERMIN; FLUORODEOXYGLUCOSE; IRINOTECAN; MITOGEN ACTIVATED PROTEIN KINASE 1; PROTEIN BCL 2; SERINE; STAT3 PROTEIN; THREONINE; TRANSCRIPTION FACTOR RELA; TYROSINE;

ADULT; APOPTOSIS; ARTICLE; CANCER SURVIVAL; CASE REPORT; CHONDROSARCOMA; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DRUG DOSE ESCALATION; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG METASTASIS; LUNG NODULE; LYMPHADENOPATHY; MALE; MULTIPLE CYCLE TREATMENT; NEEDLE BIOPSY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RADIATION DOSE; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; THORAX RADIOGRAPHY; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR REGRESSION;

APOPTOSIS; BONE NEOPLASMS; CELL SURVIVAL; CHONDROSARCOMA; DNA MUTATIONAL ANALYSIS; HUMANS; IMMUNOHISTOCHEMISTRY; ISOCITRATE DEHYDROGENASE; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROTEOMICS; PROTO-ONCOGENE PROTEINS C-BCL-2; RADIOGRAPHY, THORACIC; RECEPTORS, DEATH DOMAIN; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84869206991     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-12-0358     Document Type: Article

References (27)

1. Riedel RF, Larrier N, Dodd L, Kirsch D, Martinez S, Brigman BE. The clinical management of chondrosarcoma. Curr Treat Options Oncol 2009;10:94-106.
2. Giuffrida AY, Burgueno JE, Koniaris LG, Gutierrez JC, Duncan R, Scully SP. Chondrosarcoma in the United States (1973 to 2003): an analysis of 2890 cases from the SEER database. J Bone Joint Surg Am 2009;91:1063-72.
3. Gelderblom H, Hogendoorn PC, Dijkstra SD, van Rijswijk CS, Krol AD, Taminiau AH, et al. The clinical approach towards chondrosarcoma. Oncologist 2008;13:320-9. (Pubitemid 351679908)
4. Ashkenazi A. Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nat Rev Drug Discov 2008;7:1001-12.
5. Ashkenazi A, Herbst RS. To kill a tumor cell: the potential of proapoptotic receptor agonists. J Clin Invest 2008;118:1979-90. (Pubitemid 351872316)
6. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999;104:155-62.
7. Gong J, Yang D, Kohanim S, Humphreys R, Broemeling L, Kurzrock R. Novel in vivo imaging shows up-regulation of death receptors by paclitaxel and correlates with enhanced antitumor effects of receptor agonist antibodies. Mol Cancer Ther 2006;5:2991-3000. (Pubitemid 46092040)
8. Subbiah V, Naing A, Brown RE, Chen H, Doyle L, Lorusso P, et al. Targeted morphoproteomic profiling of Ewing's sarcoma treated with insulin-like growth factor 1 receptor (IGF1R) inhibitors: response/resistance signatures. PLoS ONE 2011;6:e18424.
9. Brown RE. Morphoproteomics: exposing protein circuitries in tumors to identify potential therapeutic targets in cancer patients. Expert Rev Proteomics 2005;2:337-48. (Pubitemid 40839745)
10. Brown RE. Morphogenomics and morphoproteomics: a role for anatomic pathology in personalized medicine. Arch Pathol Lab Med 2009;133:568-79.
11. Herbst RS, Eckhardt SG, Kurzrock R, Ebbinghaus S, O'Dwyer PJ, Gordon MS, et al. Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol 2010;28:2839-46.
12. Koehler BC, Urbanik T, Vick B, Boger RJ, Heeger S, Galle PR, et al. TRAIL-induced apoptosis of hepatocellular carcinoma cells is augmented by targeted therapies. World J Gastroenterol 2009;15:5924-35.
13. Martin V, Garcia-Santos G, Rodriguez-Blanco J, Casado-Zapico S, Sanchez-Sanchez A, Antolin I, et al. Melatonin sensitizes human malignant glioma cells against TRAIL-induced cell death. Cancer Lett 2010;287:216-23.
14. Lamothe B, Aggarwal BB. Ectopic expression of Bcl-2 and Bcl-xL inhibits apoptosis induced by TNF-related apoptosis-inducing ligand (TRAIL) through suppression of caspases-8, 7, and 3 and BID cleavage in human acute myelogenous leukemia cell line HL-60. J Interferon Cytokine Res 2002;22:269-79. (Pubitemid 34275495)
15. LeBlanc H, Lawrence D, Varfolomeev E, Totpal K, Morlan J, Schow P, et al. Tumor-cell resistance to death receptor-induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat Med 2002;8:274- 81.
16. Bovee JV, Hogendoorn PC, Wunder JS, Alman BA. Cartilage tumours and bone development: molecular pathology and possible therapeutic targets. Nat Rev Cancer 2010;10:481-8.
17. Bovee JV, van den Broek LJ, Cleton-Jansen AM, Hogendoorn PC. Up-regulation of PTHrP and Bcl-2 expression characterizes the progression of osteochondroma towards peripheral chondrosarcoma and is a late event in central chondrosarcoma. Lab Invest 2000;80:1925 - 34.
18. Rozeman LB, Hameetman L, Cleton-Jansen AM, Taminiau AH, Hogendoorn PC, Bovee JV. Absence of IHH and retention of PTHrP signalling in enchondromas and central chondrosarcomas. J Pathol 2005;205:476- 82.
19. Ivanov VN, Ghandhi SA, Zhou H, Huang SX, Chai Y, Amundson SA, et al. Radiation response and regulation of apoptosis induced by a combination of TRAIL and CHX in cells lacking mitochondrial DNA: a role for NF-kappaB-STAT3-directed gene expression. Exp Cell Res 2011;317:1548-66.
20. Rosner M, Hengstschlager M. Cytoplasmic and nuclear distribution of the protein complexes mTORC1 and mTORC2: rapamycin triggers dephosphorylation and delocalization of the mTORC2 components rictor and sin1. Hum Mol Genet 2008;17:2934-48.
21. Yang FG, Zhang ZW, Xin DQ, Shi CJ,WuJP, Guo YL, et al. Peroxisome proliferator-activated receptor gamma ligands induce cell cycle arrest and apoptosis in human renal carcinoma cell lines. Acta Pharmacol Sin 2005;26:753- 61.
22. Nishida K, Kunisada T, Shen ZN, Kadota Y, Hashizume K, Ozaki T. Chondrosarcoma and peroxisome proliferator-activated receptor. PPAR Res 2008;2008:250568.
23. Shen ZN, Nishida K, Doi H, Oohashi T, Hirohata S, Ozaki T, et al. Suppression of chondrosarcoma cells by 15-deoxy-delta 12, 14-prostaglandin J2 is associated with altered expression of Bax/Bcl-xL and p21. Biochem Biophys Res Commun 2005;328:375- 82.
24. Amary MF, Bacsi K, Maggiani F, Damato S, Halai D, Berisha F, et al. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J Pathol 2011;224:334-43.
25. Naing A, Kurzrock R. Chemotherapy resistance and retreatment: a dogma revisited. Clin Colorectal Cancer 2010;9:E1 -4.
26. von Minckwitz G, du Bois A, Schmidt M, Maass N, Cufer T, de Jongh FE, et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. J Clin Oncol 2009;27:1999-2006.
27. Horak P, Pils D, Haller G, Pribill I, Roessler M, Tomek S, et al. Contribution of epigenetic silencing of tumor necrosis factor-related apoptosis inducing ligand receptor 1 (DR4) to TRAIL resistance and ovarian cancer. Mol Cancer Res 2005;3:335-43. (Pubitemid 40905625)